Delpor
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 N Hill Dr Ste 25, Brisbane, Californ...Phone Number
(415) 480-6870Website
www.delpor.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Delpor
Delpor is a clinical-stage biopharmaceutical company that develops innovative once-yearly therapies for chronic diseases, focusing on central nervous system conditions such as Schizophrenia, Opioid Use Disorder, Spasticity, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company aims to improve medication adherence and patient outcomes by providing long-lasting treatment options. Delpor's product pipeline includes investigational therapies like DLP-114, DLP-160, and DLP-208. Their target clients include patients suffering from chronic CNS conditions and healthcare providers seeking effective treatment solutions.Explore more
Delpor Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delpor your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Delpor, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Delpor had a recent Job posting/layoffs
Product Launch: Get notified when Delpor launches new products
Earning: See what the market has to say on Delpor recently announced quarterly report
Funding: Get notified immidiatlly once Delpor has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Delpor is spiking on competitors!
Check if Delpor has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Delpor
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Delpor as Masked Content
Find more new buyers
Compare Similar Companies to Delpor
Compare insights from companies similar to Delpor, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Delpor is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Delpor is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Delpor.
Delpor financials insights
Gather financial insights about Delpor, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Unspecified
$900K
2012
Grant
$340K
2014
Grant
$222K
Delpor Tech Stack
A closer look at the technologies used by Delpor
Delpor News & Media
Delpor Announces First Subjects Dosed in Phase 1 Clinical Trial of Once or Twice-Yearly Naltrexone Implant for Opioid Addiction
BRISBANE, Calif.--(BUSINESS WIRE)--Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapeutics for chronic conditions, today announced that it has initiated and dosed the first subjects in a phase 1 clinical trial of DLP-160, a 6-12-month formulation of naltrexone for the treatment of opioid use disorder (OUD). This is an open-label study in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetiDelpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant
BRISBANE, Calif.--(BUSINESS WIRE)--Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine ImplantDelpor Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Once-Yearly Risperidone Implant
BRISBANE, Calif.--(BUSINESS WIRE)--Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies in order to develop once-yearly therapies for chronic conditions, today announced that it has initiated and dosed the first patient in a phase 1b/2a clinical trial of DLP-114, a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. This is an open-label study in stable schizophrenia patients to evaluate the safety, tDelpor Appoints Jay Smith as Chief Commercial Officer to Lead Commercialization of Once-Yearly ...
Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Delpor
Sign Up For FreeTo access detailed company insights
Delpor is a clinical-stage biopharmaceutical company that develops innovative once-yearly therapies for chronic diseases, focusing on central nervous system conditions such as Schizophrenia, Opioid Use Disorder, Spasticity, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company aims to improve medication adherence and patient outcomes by pro... Read More
